retatrutide safety clinical trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Research Concentration Overview |

Lower Cost Zepbound and Wegovy

The approval came after clinical trials involving 3,477 patients (2,519 on Zepbound and 958 on a placebo): Patients taking 5mg of Zepbound lost 15% of their body weight (study 1) Patients taking 10mg of Zepbound lost 19.5% (study 1) and 12.8% (study 2) of their body weight Patients taking 15mg of Zepbound lost 20.9% (study 1) and 14.7% (study 2) of their body weight Patients taking the placebo lost 3.1% (study 1) and 3.2% (study 2) of their body weight Zepbound was released to market on December 5, 2023, with six available dosages available to those with a prescription: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg

This reflects obesity's chronic nature and suggests that ongoing treatment may be necessary for sustained weight management in many individuals

For months, the conversation around GLP-1 medications like Ozempic, Wegovy and Mounjaro has revolved around one thing: they make people eat less